Ascendis Pharma AS (NAS:ASND)
$ 137.5 -2.81 (-2%) Market Cap: 8.39 Bil Enterprise Value: 8.62 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 71/100

Ascendis Pharma A/S at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2021 / 04:30PM GMT
Release Date Price: $157.32 (+2.46%)
David Neil Lebowitz;Timothy Lee
Morgan Stanley, Research Division - VP

Hello and good afternoon. Welcome again to the 19th Annual Global Healthcare Conference. Before I get started, let me read the requisite disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

And with that, let me introduce myself. I'm David Lebowitz, one of the biotechnology analysts at Morgan Stanley. And I'm happy to have with me from Ascendis, CEO, Jan Mikkelsen; and CFO, Scott Smith. Ascendis is now a commercial-stage biotechnology with the recent approval of SKYTROFA for pediatric growth hormone deficiency, but they also have a deep platform technology called TransCon, which can be applied to a wide variety of diseases.

I guess, Jan, if you could start off just giving a top-level overview of the company and your mission.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot